News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News Ironwood crashes down as FDA seeks new phase 3 trial Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.
News Failed trial knocks back wider use of BMS' Camzyos Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.
News Scancell taps into NHS matchmaking service for cancer trial Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.
News Pfizer's weight-loss aspirations are dealt a heavy blow Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.
News Novartis plans $23bn manufacturing, R&D spend in US Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.
Patients Prevention for a healthier, more productive society During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
